Hepatitis B Virus
37
3
3
19
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.7%
1 terminated out of 37 trials
95.0%
+8.5% vs benchmark
19%
7 trials in Phase 3/4
37%
7 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (37)
HepB mAb19 in Individuals With Chronic Hepatitis B Infection
A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients
Impact of Hepatitis B Virus on Inflammatory Bowel Disease
To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant Patients
Obeticholic Acid Among Chronic HBV Patients with Hepatic Steatosis : Clinical and Portal Doppler Outcomes
Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting
Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy
Mutations of the Pre-core Region of Hepatite B Virus (HBV)
NK Cell Deregulation in HBV Patients
A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District
Efficacy of HBVaxpro40© and Fendrix© in Patients With Chronic Liver Disease.
Effects of Antiviral Therapy on Patients With HBV-related HCC
Hepatocellular Carcinoma in HIV-infected Patients
Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Use of Dynavax Heplisav B in Healthcare Workers Previously Vaccinated With 3-dose Vaccine Who Failed to Demonstrate Seroprotection
Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment